<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3648">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511923</url>
  </required_header>
  <id_info>
    <org_study_id>NUIG-2020-003</org_study_id>
    <nct_id>NCT04511923</nct_id>
  </id_info>
  <brief_title>Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury</brief_title>
  <acronym>CHARTER-Irl</acronym>
  <official_title>Can Nebulised HepArin Reduce acuTE Lung Injury in Patients With SARS-CoV-2 Requiring Respiratory Support in Ireland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Hospital Galway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College Hospital Galway</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We present a randomised open label phase Ib/IIa trial of nebulised unfractionated heparin to&#xD;
      evaluate the effect of nebulised unfractionated heparin on the procoagulant response in ICU&#xD;
      patients with SARS-CoV-2 requiring advanced respiratory support. As this is one of the first&#xD;
      studies of nebulised heparin in COVID 19 lung disease we will assess safety as a co-primary&#xD;
      outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>D-dimer profile</measure>
    <time_frame>Up to day 10.</time_frame>
    <description>Effect of nebulised heparin on d-dimer profile, assessed via d-dimer AUC and via a mixed effects model, with data collected on days 1, 3, 5 and 10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequenccy of Severe Adverse Outcomes</measure>
    <time_frame>Up to day 60</time_frame>
    <description>Safety of nebulised heparin delivered by aerogen solo nebuliser in patients with COVID-19 induced severe respiratory failure, as measured by the incidence of severe adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygenation Index</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Determine the impact of nebulised heparin on oxygenation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indices of Inflammation</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Effect of nebulised heparin on indices of inflammation (Interleukin (IL)-1β, IL-6, IL-8, IL-10 and soluble TNF receptor 1 (sTNFR1), C-reactive protein, procalcitonin, Ferritin,) will be assessed (AUC on days 1, 3, 5 and 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratios of Indices of Inflammation</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Effect of nebulised heparin on the ratios of IL-1β/IL-10 and IL-6/IL-10 will also be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indices of Coagulation</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Effect of nebulised heparin on other indices of coagulation (Fibrinogen; lactate dehydrogenase) will be assessed (AUC on days 1, 3, 5 and 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quasi-Static Lung Compliance</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Determine the effect of nebulised heparin on Quasi-Static Lung Compliance (i.e. tidal volume/(Plateau pressure-PEEP) measured on days 1,3,5,10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to separation from advanced respiratory support</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Time to separation from advanced respiratory support, where non survivors are treated as though not separated from advanced respiratory support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number treated with neuromuscular blockers</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Number treated with neuromuscular blockers instituted after enrolment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number treated with Prone positioning</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Number treated with prone positioning instituted after enrolment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number treated with extra-corporeal membrane oxygenation</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Number treated with extra-corporeal membrane oxygenation instituted after enrolment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number requiring Tracheostomy</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Number tracheotomised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to separation from invasive ventilation among survivors</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Time to separation from invasive ventilation among survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge to ward</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Time to separation from the ICU to day 28, where non-survivors to day 28 are treated as though not separated from invasive care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge to ward in survivors</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Time to discharge from the ICU to day 28, among survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>Up to day 60</time_frame>
    <description>Survival to day 28; Survival to day 60; and Survival to hospital discharge, censored at day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients residing at home or in a community setting at day 60</measure>
    <time_frame>Up to day 60</time_frame>
    <description>Number residing at home or in a community setting at day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of surviving patients residing at home or in a community</measure>
    <time_frame>Up to day 60</time_frame>
    <description>Number residing at home or in a community setting at day 60, among survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilatory ratio</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Effect of nebulised heparin on ventilatory ratio measured every 6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number treated with awake prone positioning</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Number of patients treated with awake prone positioning</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <condition>ARDS, Human</condition>
  <condition>Lung Injury, Acute</condition>
  <condition>Ventilation Perfusion Mismatch</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard care plus nebulised unfractionated heparin 25000 units every 6 hours for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulised heparin</intervention_name>
    <description>Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days</description>
    <arm_group_label>Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible, a patient must satisfy all these inclusion criteria:&#xD;
&#xD;
          1. Confirmed or suspected COVID-19. Note, if 'suspected', results must be pending or&#xD;
             testing intended&#xD;
&#xD;
          2. Ability to obtain informed consent/assent to participate in study&#xD;
&#xD;
          3. Age 18 years or older&#xD;
&#xD;
          4. Requiring high flow nasal oxygen or positive pressure ventilator support or invasive&#xD;
             mechanical ventilation for a time period of no greater than 48 hours&#xD;
&#xD;
          5. D-dimers &gt; 200 ng/ml&#xD;
&#xD;
          6. PaO2 to FIO2 ratio less than or equal to 300&#xD;
&#xD;
          7. Acute opacities on chest imaging affecting at least one lung quadrant. Note 'Acute&#xD;
             opacities' do not include effusions, lobar/lung collapse or nodules&#xD;
&#xD;
          8. Currently in a higher level of care area designated for inpatient care of patients&#xD;
             where therapies including non-positive pressure ventilatory support can be provided.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        To be eligible, a patient must have none of these exclusion criteria:&#xD;
&#xD;
          1. Enrolled in another clinical trial that is unapproved for co-enrolment&#xD;
&#xD;
          2. Heparin allergy or heparin-induced thrombocytopaenia&#xD;
&#xD;
          3. APTT &gt; 100 seconds&#xD;
&#xD;
          4. Platelet count &lt; 50 x 109 per L&#xD;
&#xD;
          5. Pulmonary bleeding, which is frank bleeding in the trachea, bronchi or lungs with&#xD;
             repeated haemoptysis or requiring repeated suctioning&#xD;
&#xD;
          6. Uncontrolled bleeding&#xD;
&#xD;
          7. Pregnant or suspected pregnancy (Urine or serum HCG will be recorded)&#xD;
&#xD;
          8. Receiving or about to commence ECMO or HFOV&#xD;
&#xD;
          9. Myopathy, spinal cord injury, or nerve injury or disease with a likely prolonged&#xD;
             incapacity to breathe independently e.g. Guillain-Barre syndrome&#xD;
&#xD;
         10. Usually receives home oxygen&#xD;
&#xD;
         11. Dependent on others for personal care due to physical or cognitive decline (pre-morbid&#xD;
             status)&#xD;
&#xD;
         12. Death is imminent or inevitable within 24 hours&#xD;
&#xD;
         13. The clinical team would not be able to set up the study nebuliser and ventilator&#xD;
             circuit as required including with active humidification&#xD;
&#xD;
         14. Clinician objection.&#xD;
&#xD;
         15. The use or anticipated use of nebulised tobramycin during this clinical episode&#xD;
&#xD;
         16. Any other specific contraindication to anticoagulation including prophylactic&#xD;
             anticoagulation not otherwise listed here&#xD;
&#xD;
         17. Relapse in clinical condition in patient that had fully weaned from advanced&#xD;
             respiratory support&#xD;
&#xD;
         18. Any systemic anticoagulation other than prophylactic anticoagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Laffey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Anaesthesia and Intensive Care Medicine, National University of Ireland, Galway, Ireland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Laffey</last_name>
    <phone>+353 91 544074</phone>
    <email>John.laffey@nuigalway.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Cosgrave</last_name>
    <phone>+35391544074</phone>
    <email>davidw.cosgrave@hse.ie</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cosgrave, MDBChBAOFCAI</last_name>
      <email>davidw.cosgrave@hse.ie</email>
    </contact>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Hospital Galway</investigator_affiliation>
    <investigator_full_name>John Laffey</investigator_full_name>
    <investigator_title>Professor, Anaesthesia and Intensive Care Medicine, School of Medicine, NUI Galway; Consultant, Anaesthesia and ICM, Galway University Hospitals; Vice-Dean Research, College of Medicine, Nursing</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Investigator will consider requests to share anonymised data for the purposes of meta-analysis following discussion with the sponsor.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Investigator will consider release of the above data once the study report has been completed.</ipd_time_frame>
    <ipd_access_criteria>To be confirmed, prior to enrollment of the first patient.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

